Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures

Japanese Journal of Ophthalmology

Volumn 57, Issue 2, 2013, Pages 133-149

  Mayama, Chihiro ^a   Araie, Makoto ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b The Mutualaid Association of Public School Teachers)   (Japan)

Author keywords

Blood flow; In vivo measurements; Optic nerve head; Systemic drugs; Topical antiglaucoma drug

Indexed keywords

ACETAZOLAMIDE; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; BUNAZOSIN; CALCIUM CHANNEL BLOCKING AGENT; CARTEOLOL; DIHYDROBUNOLOL; DORZOLAMIDE; DRUG METABOLITE; ENDOTHELIN 1; IGANIDIPINE; LATANOPROST; LEVOBUNOLOL; NICARDIPINE; NIFEDIPINE; NILVADIPINE; NIMODIPINE; NIPRADILOL; PHENYLEPHRINE; PILOCARPINE; PRANIDIPINE; TAFLUPROST; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNOPROSTONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; PROSTAGLANDIN DERIVATIVE;

ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; BLOOD FLOW VELOCITY; BLOOD RETINA BARRIER; BLOOD VESSEL DIAMETER; COLOR ULTRASOUND FLOWMETRY; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TISSUE LEVEL; EYE BLOOD FLOW; EYE EXAMINATION; GLAUCOMA; HEART ARRHYTHMIA; HEMODYNAMICS; HUMAN; HYPERTENSION; INTRACRANIAL HYPOTENSION; INTRAOCULAR PRESSURE; LASER SPECKLE FLOWGRAPHY; LOW TENSION GLAUCOMA; MIGRAINE; MYDRIASIS; NONHUMAN; OCULAR PERFUSION PRESSURE; OPEN ANGLE GLAUCOMA; OPTIC NERVE; OPTIC NERVE HEAD; PERFUSION PRESSURE; PRIORITY JOURNAL; PULSATILE FLOW; RESISTIVE INDEX; REVIEW; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TISSUE DISTRIBUTION; VASCULARIZATION; VASOCONSTRICTION; BLOOD FLOW; OPTIC DISK; OPTIC NERVE DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD FLOW VELOCITY; CARBONIC ANHYDRASE INHIBITORS; CHOLINERGIC AGONISTS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OPTIC DISK; OPTIC NERVE DISEASES; PROSTAGLANDINS, SYNTHETIC; REGIONAL BLOOD FLOW;

MLCS; MLOWN;

EID: 84878969085     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-012-0220-x     Document Type: Review

References (252)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-7. (Pubitemid 43325451)
2. Leske MC, Connell AM, Wu SY, Nemesure B, Li X, Schachat A, et al. Incidence of open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group. Arch Ophthalmol. 2001;119:89-95. (Pubitemid 32096390)
3. de Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Hofman A, de Jong PT. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology. 2005;112:1487-93. (Pubitemid 41725401)
4. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429-40.
5. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56. (Pubitemid 36401765)
6. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487-97.
7. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:498-505.
8. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-79. (Pubitemid 36105431)
9. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-13 (discussion 829-30). (Pubitemid 34620348)
10. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965-72. (Pubitemid 350016362)
11. Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008;115:85-93. (Pubitemid 350309410)
12. Bonovas S, Peponis V, Filioussi K. Diabetes mellitus as a risk factor for primary open-angle glaucoma: a meta-analysis. Diabet Med. 2004;21:609-14. (Pubitemid 38746283)
13. Hayreh SS. The role of age and cardiovascular disease in glaucomatous optic neuropathy. Surv Ophthalmol. 1999;43(Suppl 1):S27-42. (Pubitemid 29328577)
14. Graham SL, Drance SM. Nocturnal hypotension: role in glaucoma progression. Surv Ophthalmol. 1999;43(Suppl 1):S10-6. (Pubitemid 29328575)
15. Comoglu S, Yarangumeli A, Koz OG, Elhan AH, Kural G. Glaucomatous visual field defects in patients with migraine. J Neurol. 2003;250:201-6. (Pubitemid 36223095)
16. Michelson G, Langhans MJ, Harazny J, Dichtl A. Visual field defect and perfusion of the juxtapapillary retina and the neuroretinal rim area in primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 1998;236:80-5. (Pubitemid 28080507)
17. Findl O, Rainer G, Dallinger S, Dorner G, Polak K, Kiss B, et al. Assessment of optic disk blood flow in patients with open-angle glaucoma. Am J Ophthalmol. 2000;130:589-96.
18. Ciancaglini M, Carpineto P, Costagliola C, Matropasqua L. Perfusion of the optic nerve head and visual field damage in glaucomatous patients. Graefes Arch Clin Exp Ophthalmol. 2001;239:549-55. (Pubitemid 32816173)
19. Yaoeda K, Shirakashi M, Fukushima A, Funaki S, Funaki H, Abe H, et al. Relationship between optic nerve head microcirculation and visual field loss in glaucoma. Acta Ophthalmol Scand. 2003;81:253-9. (Pubitemid 36806263)
20. Nicolela MT, Walman BE, Buckley AR, Drance SM. Ocular hypertension and primary open-angle glaucoma: a comparative study of their retrobulbar blood flow velocity. J Glaucoma. 1996;5:308-10. (Pubitemid 26364640)
21. Duijm HF, van den Berg TJ, Greve EL. Choroidal haemodynamics in glaucoma. Br J Ophthalmol. 1997;81:735-42. (Pubitemid 27453579)
22. Evans DW, Harris A, Garrett M, Chung HS, Kagemann L. Glaucoma patients demonstrate faulty autoregulation of ocular blood flow during posture change. Br J Ophthalmol. 1999;83:809-13. (Pubitemid 29324793)
23. Liu CJ, Chiou HJ, Chiang SC, Chou JC, Chou YH, Liu JH. Variations in ocular hemodynamics in patients with early and late glaucoma. Acta Ophthalmol Scand. 1999;77:658-62. (Pubitemid 30006806)
24. Gherghel D, Orgul S, Gugleta K, Flammer J. Retrobulbar blood flow in glaucoma patients with nocturnal over-dipping in systemic blood pressure. Am J Ophthalmol. 2001;132:641-7. (Pubitemid 33031280)
25. Galassi F, Sodi A, Ucci F, Renieri G, Pieri B, Baccini M. Ocular hemodynamics and glaucoma prognosis: a color Doppler imaging study. Arch Ophthalmol. 2003;121:1711-5. (Pubitemid 37517437)
26. Leske MC, Wu SY, Nemesure B, Hennis A. Incident open-angle glaucoma and blood pressure. Arch Ophthalmol. 2002;120:954-9. (Pubitemid 34755549)
27. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol. 1995;113:216-21.
28. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A. Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology. 2000;107:1287-93.
29. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119:1819-26. (Pubitemid 33139614)
30. Mitchell P, Leung H, Wang JJ, Rochtchina E, Lee AJ, Wong TY, et al. Retinal vessel diameter and open-angle glaucoma: the Blue Mountains Eye Study. Ophthalmology. 2005;112:245-50. (Pubitemid 40202559)
31. Amerasinghe N, Aung T, Cheung N, Fong CW, Wang JJ, Mitchell P, et al. Evidence of retinal vascular narrowing in glaucomatous eyes in an Asian population. Invest Ophthalmol Vis Sci. 2008;49:5397-402.
32. Leske MC, Warheit-Roberts L, Wu SY. Open-angle glaucoma and ocular hypertension: the Long Island Glaucoma Case-control Study. Ophthalmic Epidemiol. 1996;3:85-96. (Pubitemid 26237522)
33. Oku H, Sugiyama T, Kojima S, Watanabe T, Azuma I. Experimental optic cup enlargement caused by endothelin-1-induced chronic optic nerve head ischemia. Surv Ophthalmol. 1999;44(Suppl 1):S74-84.
34. Cioffi GA, Sullivan P. The effect of chronic ischemia on the primate optic nerve. Eur J Ophthalmol. 1999;9(Suppl 1):S34-6. (Pubitemid 29179933)
35. Hayreh SS. Anatomy and physiology of the optic nerve head. Trans Am Acad Ophthalmol Otolaryngol. 1974;78:OP240-54.
36. Onda E, Cioffi GA, Bacon DR, Van Buskirk EM. Microvasculature of the human optic nerve. Am J Ophthalmol. 1995;120:92-102.
37. Lieberman MF, Maumenee AE, Green WR. Histologic studies of the vasculature of the anterior optic nerve. Am J Ophthalmol. 1976;82:405-23.
38. Anderson DR. Vascular supply to the optic nerve of primates. Am J Ophthalmol. 1970;70:341-51.
39. Anderson DR, Braverman S. Reevaluation of the optic disk vasculature. Am J Ophthalmol. 1976;82:165-74.
40. Cioffi GA, Granstam E, Alm A. Ocular circulation. In: Kaufman PL, Alm A, editors. Adler's physiology of the eye. St. Louis: Mosby; 2003. p. 747-84.
41. Cunha-Vaz JG. The blood-retinal barriers. Doc Ophthalmol. 1976;41:287-327.
42. Tso MO, Shih CY, McLean IW. Is there a blood-brain barrier at the optic nerve head? Arch Ophthalmol. 1975;93:815-25.
43. Flage T. A defect in the blood-retina barrier in the optic nerve head region in the rabbit and the monkey. Acta Ophthalmol (Cph). 1980;58:645-51. (Pubitemid 10001371)
44. Hofman P, Hoyng P, vanderWerf F, Vrensen GF, Schlingemann RO. Lack of blood-brain barrier properties in microvessels of the prelaminar optic nerve head. Investig Ophthalmol Vis Sci. 2001;42:895-901. (Pubitemid 32289782)
45. Araie M, Takase M, Sakai Y, Ishii Y, Yokoyama Y, Kitagawa M. Beta-adrenergic blockers: ocular penetration and binding to the uveal pigment. Jpn J Ophthalmol. 1982;26:248-63. (Pubitemid 12038008)
46. Acheampong AA, Breau A, Shackleton M, Luo W, Lam S, Tang-Liu DD. Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits. J Ocul Pharmacol Ther. 1995;11:489-502.
47. Mizuno K, Koide T, Saito N, Fujii M, Nagahara M, Tomidokoro A, et al. Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys. Investig Ophthalmol Vis Sci. 2002;43:3243-50.
48. 2+ antagonist: ocular and periocular penetration after instillation. Investig Ophthalmol Vis Sci. 2003;44:1169-77. (Pubitemid 36297837)
49. 2+ antagonist, increases ipsilateral optic nerve head circulation in rabbits and cynomolgus monkeys. Curr Eye Res. 2004;29:67-73. (Pubitemid 39389443)
50. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol. 2002;47(Suppl 1):S41-52. (Pubitemid 35232218)
51. Mizuno K, Koide T, Shimada S, Mori J, Sawanobori K, Araie M. Route of penetration of topically instilled nipradilol into the ipsilateral posterior retina. Investig Ophthalmol Vis Sci. 2009;50:2839-47.
52. Mizuno K, Koide T, Yoshimura M, Araie M. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Investig Ophthalmol Vis Sci. 2001;42:688-94. (Pubitemid 32206909)
53. Ichikawa M, Okada Y, Asai Y, Hara H, Ishii K, Araie M. Effects of topically instilled bunazosin, an alpha1-adrenoceptor antagonist, on constrictions induced by phenylephrine and ET-1 in rabbit retinal arteries. Investig Ophthalmol Vis Sci. 2004;45:4041-8. (Pubitemid 39411159)
54. Kronfeld PC. Eserine and pilocarpine: our 100-year-old allies. Surv Ophthalmol. 1970;14:479-85.
55. Weber A. Uber Calabar und seine therapeutisch Verwendung. Graefes Arch Klin Exp Ophthalmol. 1876;22:215-75 (in German).
56. Chiou GC, Yan HY. Effects of antiglaucoma drugs on the blood flow in rabbit eyes. Ophthalmic Res. 1986;18:265-9. (Pubitemid 17170451)
57. Green K, Hatchett TL. Regional ocular blood flow after chronic topical glaucoma drug treatment. Acta Ophthalmol (Cph). 1987;65:503-6.
58. Yoshitomi T, Ishikawa H, Hayashi E. Pharmacological effects of pilocarpine on rabbit ciliary artery. Curr Eye Res. 2000;20:254-9. (Pubitemid 30428154)
59. Chiou GC, Chen YJ. Effects of antiglaucoma drugs on ocular blood flow in ocular hypertensive rabbits. J Ocul Pharmacol. 1993;9:13-24. (Pubitemid 23100649)
60. Schmetterer L, Strenn K, Findl O, Breiteneder H, Graselli U, Agneter E, et al. Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. Clin Pharmacol Ther. 1997;61:583-95. (Pubitemid 27261762)
61. Shaikh MH, Mars JS. The acute effect of pilocarpine on pulsatile ocular blood flow in ocular hypertension. Eye (London). 2001;15:63-6. (Pubitemid 32258219)
62. Mittag TW, Serle J, Schumer R, Brodie S, Stegman D, Schmidt KG, et al. Studies of the ocular pulse in primates. Surv Ophthalmol. 1994;38(Suppl):S183- 90. (Pubitemid 124017815)
63. Van Buskirk EM, Bacon DR, Fahrenbach WH. Ciliary vasoconstriction after topical adrenergic drugs. Am J Ophthalmol. 1990;109:511-7. (Pubitemid 20144017)
64. Sugiyama K, Bacon D, Cioffi G, Fahrenback W, Van Buskirk E. The effects of phenylephrine on the ciliary body, optic nerve head microvasculature in rabbits. J Glaucoma. 1992;1:156-64.
65. Takayama J, Mishima A, Ishii K. Effects of topical phenylephrine on blood flow in the posterior segments of monkey, aged human eyes. Jpn J Ophthalmol. 2004;48:243-8. (Pubitemid 38691432)
66. Takayama J, Mayama C, Mishima A, Nagahara M, Tomidokoro A, Araie M. Topical phenylephrine decreases blood velocity in the optic nerve head, increases resistive index in the retinal arteries. Eye. 2009;23:827-34.
67. Mayama C, Ishii K, Saeki T, Ota T, Tomidokoro A, Araie M. Effects of topical phenylephrine, tafluprost on optic nerve head circulation in monkeys with unilateral experimental glaucoma. Investig Ophthalmol Vis Sci. 2010;51:4117-24.
68. Gharagozloo NZ, Relf SJ, Brubaker RF. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology. 1988;95:1217-20.
69. Toris CB, Tafoya ME, Camras CB, Yablonski ME. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102:456-61.
70. Robin AL, Pollack IP, House B, Enger C. Effects of ALO 2145 on intraocular pressure following argon laser trabeculoplasty. Arch Ophthalmol. 1987;105:646-50. (Pubitemid 17061111)
71. Brown RH, Stewart RH, Lynch MG, Crandall AS, Mandell AI, Wilensky JT, et al. ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery. Ophthalmology. 1988;95:378-84. (Pubitemid 18075771)
72. Kitazawa Y, Taniguchi T, Sugiyama K. Use of apraclonidine to reduce acute intraocular pressure rise following Q-switched Nd:YAG laser iridotomy. Ophthalmic Surg. 1989;20:49-52.
73. Robin AL. Short-term effects of unilateral 1 % apraclonidine therapy. Arch Ophthalmol. 1988;106:912-5.
74. Serdahl CL, Galustian J, Lewis RA. The effects of apraclonidine on conjunctival oxygen tension. Arch Ophthalmol. 1989;107:1777-9. (Pubitemid 20013140)
75. Celiker UO, Celebi S, Celiker H, Celebi H. Effect of topical apraclonidine on flow properties of central retinal and ophthalmic arteries. Acta Ophthalmol Scand. 1996;74:151-4. (Pubitemid 26146619)
76. Oruc S, Sener EC. A comparative study on the effects of apraclonidine and timolol on the ophthalmic blood flow velocity waveforms. Int Ophthalmol. 1999;23:69-73. (Pubitemid 32042085)
77. Kim TW, Kim DM. Effects of 0.5 % apraclonidine on optic nerve head and peripapillary retinal blood flow. Br J Ophthalmol. 1997;81:1070-2. (Pubitemid 27526826)
78. Avunduk AM, Sari A, Akyol N, Ozturk O, Kapicioglu Z, Erdol H, et al. The one-month effects of topical betaxolol, dorzolamide and apraclonidine on ocular blood flow velocities in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica. 2001;215:361-5. (Pubitemid 32786196)
79. Gabelt BT, Robinson JC, Hubbard WC, Peterson CM, Debink N, Wadhwa A, et al. Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys. Exp Eye Res. 1994;59:633-44.
80. Maus TL, Nau C, Brubaker RF. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol. 1999;117:586-91. (Pubitemid 29218423)
81. Schmidt KG, Klingmuller V, Gouveia SM, Osborne NN, Pillunat LE. Short posterior ciliary artery, central retinal artery, and choroidal hemodynamics in brimonidine-treated primary open-angle glaucoma patients. Am J Ophthalmol. 2003;136:1038-48. (Pubitemid 37485770)
82. Vetrugno M, Maino A, Cantatore F, Ruggeri G, Cardia L. Acute and chronic effects of brimonidine 0.2 % on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: an open-label, uncontrolled, prospective study. Clin Ther. 2001;23:1519-28. (Pubitemid 32912798)
83. Carlsson AM, Chauhan BC, Lee AA, LeBlanc RP. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension. Am J Ophthalmol. 2000;129:297-301. (Pubitemid 30126073)
84. Liu CJ, Ko YC, Cheng CY, Chou JC, Hsu WM, Liu JH. Effect of latanoprost 0.005 % and brimonidine tartrate 0.2 % on pulsatile ocular blood flow in normal tension glaucoma. Br J Ophthalmol. 2002;86:1236-9. (Pubitemid 35238602)
85. Feke GT, Hazin R, Grosskreutz CL, Pasquale LR. Effect of brimonidine on retinal blood flow autoregulation in primary open-angle glaucoma. J Ocul Pharmacol Ther. 2011;27:347-52.
86. Ohkubo H, Chiba S. Pharmacological analysis of vasoconstriction of isolated canine ophthalmic and ciliary arteries to alpha-adrenoceptor agonists. Exp Eye Res. 1987;45:263-70. (Pubitemid 17130006)
87. Sugiyama T. Effects of topically applied bunazosin hydrochloride on choroidal capillary blood flow and intraocular pressure of rabbit eye. Nihon Ganka Gakkai Zasshi. 1991;95:449-54 (in Japanese).
88. Sugiyama T, Oku H, Moriya S, Shimizu K, Azuma I. Evaluation of bunazosin hydrochloride with a model of ocular circulation disturbance induced by endothelin-1. Nihon Ganka Gakkai Zasshi. 1994;98:63-8 (in Japanese). (Pubitemid 24062375)
89. Goto W, Oku H, Okuno T, Sugiyama T, Ikeda T. Amelioration of endothelin-1-induced optic nerve head ischemia by topical bunazosin. Curr Eye Res. 2005;30:81-91. (Pubitemid 40516084)
90. Goto W, Oku H, Okuno T, Sugiyama T, Ikeda T. Amelioration by topical bunazosin hydrochloride of the impairment in ocular blood flow caused by nitric oxide synthase inhibition in rabbits. J Ocul Pharmacol Ther. 2003;19:63-73. (Pubitemid 36249881)
91. Trew DR, Wright LA, Smith SE. Ocular responses in healthy subjects to topical bunazosin 0.3 % - an alpha 1-adrenoceptor antagonist. Br J Ophthalmol. 1991;75:411-3.
92. Elena PP, Denis P, Kosina-Boix M, Saraux H, Lapalus P. Beta adrenergic binding sites in the human eye: an autoradiographic study. J Ocul Pharmacol. 1990;6:143-9. (Pubitemid 20299335)
93. Millar JC, Wilson WS, Carr RD, Humphries RG. Drug effects on intraocular pressure and vascular flow in the bovine perfused eye using radiolabelled microspheres. J Ocul Pharmacol Ther. 1995;11:11-23.
94. Hayashi-Morimoto R, Yoshitomi T, Ishikawa H, Hayashi E, Sato Y. Effects of beta antagonists on mechanical properties in rabbit ciliary artery. Graefes Arch Clin Exp Ophthalmol. 1999;237:661-7. (Pubitemid 29358764)
95. Chiou GC, Chen YJ. Effects of d- and l-isomers of timolol on retinal and choroidal blood flow in ocular hypertensive rabbit eyes. J Ocul Pharmacol. 1992;8:183-90.
96. Jay WM, Aziz M, Green K. Effect of topical epinephrine and timolol on ocular and optic nerve blood flow in phakic and aphakic rabbit eyes. Curr Eye Res. 1984;3:1199-202. (Pubitemid 14012201)
97. Tomidokoro A, Araie M, Tamaki Y, Tomita K. In vivo measurement of iridial circulation using laser speckle phenomenon. Investig Ophthalmol Vis Sci. 1998;39:364-71. (Pubitemid 28093874)
98. Tamaki Y, Araie M, Tomita K, Tomidokoro A. Effect of topical timolol on tissue circulation in optic nerve head. Jpn J Ophthalmol. 1997;41:297-304. (Pubitemid 27474580)
99. Ishii K, Araie M. Effect of topical timolol on optic nerve head circulation in the cynomolgus monkey. Jpn J Ophthalmol. 2000;44:630-3.
100. Haefliger IO, Lietz A, Griesser SM, Ulrich A, Schotzau A, Hendrickson P, et al. Modulation of Heidelberg Retinal Flowmeter parameter flow at the papilla of healthy subjects: effect of carbogen, oxygen, high intraocular pressure, and beta-blockers. Surv Ophthalmol. 1999;43(Suppl 1):S59-65. (Pubitemid 29328580)
101. Netland PA, Schwartz B, Feke GT, Takamoto T, Konno S, Goger DG. Diversity of response of optic nerve head circulation to timolol maleate in gel-forming solution. J Glaucoma. 1999;8:164-71. (Pubitemid 32435874)
102. Fuchsjager-Mayrl G, Wally B, Rainer G, Buehl W, Aggermann T, Kolodjaschna J, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2005;89:1293-7. (Pubitemid 41638868)
103. Tamaki Y, Araie M, Tomita K, Nagahara M, Tomidokoro A. Effect of topical beta-blockers on tissue blood flow in the human optic nerve head. Curr Eye Res. 1997;16:1102-10. (Pubitemid 27487320)
104. Grunwald JE. Effect of timolol maleate on the retinal circulation of human eyes with ocular hypertension. Investig Ophthalmol Vis Sci. 1990;31:521-6. (Pubitemid 20117069)
105. Yoshida A, Ogasawara H, Fujio N, Konno S, Ishiko S, Kitaya N, et al. Comparison of short- and long-term effects of betaxolol and timolol on human retinal circulation. Eye (London). 1998;12(Pt 5):848-53. (Pubitemid 28482812)
106. Nicolela MT, Buckley AR, Walman BE, Drance SM. A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels. Am J Ophthalmol. 1996;122:784-9. (Pubitemid 26412424)
107. Altan-Yaycioglu R, Turker G, Akdol S, Acunas G, Izgi B. The effects of beta-blockers on ocular blood flow in patients with primary open angle glaucoma: a color Doppler imaging study. Eur J Ophthalmol. 2001;11:37-46. (Pubitemid 32233927)
108. Bergstrand IC, Heijl A, Wollmer P, Hansen F, Harris A. Timolol increased retrobulbar flow velocities in untreated glaucoma eyes but not in ocular hypertension. Acta Ophthalmol Scand. 2001;79:455-61. (Pubitemid 32962833)
109. Lubeck P, Orgul S, Gugleta K, Gherghel D, Gekkieva M, Flammer J. Effect of timolol on anterior optic nerve blood flow in patients with primary open-angle glaucoma as assessed by the Heidelberg retina flowmeter. J Glaucoma. 2001;10:13-7. (Pubitemid 32151789)
110. Evans DW, Harris A, Cantor LB. Primary open-angle glaucoma patients characterized by ocular vasospasm demonstrate a different ocular vascular response to timolol versus betaxolol. J Ocul Pharmacol Ther. 1999;15:479-87.
111. Galassi F, Sodi A, Renieri G, Ucci F, Pieri B, Harris A, et al. Effects of timolol and dorzolamide on retrobulbar hemodynamics in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica. 2002;216:123-8. (Pubitemid 34264216)
112. Harris A, Spaeth GL, Sergott RC, Katz LJ, Cantor LB, Martin BJ. Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma. Am J Ophthalmol. 1995;120:168-75.
113. Trew DR, Smith SE. Postural studies in pulsatile ocular blood flow: II. Chronic open angle glaucoma. Br J Ophthalmol. 1991;75:71-5.
114. Claridge KG, Smith SE. Diurnal variation in pulsatile ocular blood flow in normal and glaucomatous eyes. Surv Ophthalmol. 1994;38(Suppl):S198-205. (Pubitemid 124017817)
115. Morsman CD, Bosem ME, Lusky M, Weinreb RN. The effect of topical beta-adrenoceptor blocking agents on pulsatile ocular blood flow. Eye (London). 1995;9(Pt 3):344-7.
116. Manint Veld AJ, Schalekamp MA. How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. Br J Clin Pharmacol. 1982;13:245S-57S. (Pubitemid 13144801)
117. Janczewski P, Boulanger C, Iqbal A, Vanhoutte PM. Endothelium-dependent effects of carteolol. J Pharmacol Exp Ther. 1988;247:590-5.
118. Tomidokoro A, Tamaki Y, Araie M, Tomita K, Muta K. Effect of topical carteolol on iridial circulation in pigmented rabbit eyes. Jpn J Ophthalmol. 1998;42:180-5. (Pubitemid 28342359)
119. Tamaki Y, Araie M, Tomita K, Tomidokoro A. Effect of topical carteolol on tissue circulation in the optic nerve head. Jpn J Ophthalmol. 1998;42:27-32. (Pubitemid 28097430)
120. Sugiyama T, Azuma I, Araie M, Fujisawa S, Urashima H, Nagasawa M. Effect of continuous intravenous infusion of carteolol chloride on tissue blood flow in rabbit optic nerve head. Jpn J Ophthalmol. 1999;43:490-4.
121. Grunwald JE, Delehanty J. Effect of topical carteolol on the normal human retinal circulation. Investig Ophthalmol Vis Sci. 1992;33:1853-6.
122. Tamaki Y, Araie M, Tomita K, Tomidokoro A, Nagahara M. Effects of topical adrenergic agents on tissue circulation in rabbit and human optic nerve head evaluated with laser speckle tissue circulation analyzer. Surv Ophthalmol. 1997;42(Suppl 1):S52-63.
123. Mizuki K, Yamazaki Y. Effect of carteolol hydrochloride on ocular blood flow dynamics in normal human eyes. Jpn J Ophthalmol. 2000;44:570.
124. Vuori ML, Ali-Melkkila T, Kaila T, Iisalo E, Saari KM. Beta 1- and beta 2-antagonist activity of topically applied betaxolol and timolol in the systemic circulation. Acta Ophthalmol (Cph). 1993;71:682-5. (Pubitemid 24002333)
125. Hoste AM, Sys SU. The relaxant action of betaxolol on isolated bovine retinal microarteries. Curr Eye Res. 1994;13:483-7. (Pubitemid 24215984)
126. Orgul S, Mansberger S, Bacon DR, Van Buskirk EM, Cioffi GA. Optic nerve vasomotor effects of topical beta-adrenergic antagonists in rabbits. Am J Ophthalmol. 1995;120:441-7.
127. Sato T, Muto T, Ishibashi Y, Roy S. Short-term effect of beta-adrenoreceptor blocking agents on ocular blood flow. Curr Eye Res. 2001;23:298-306. (Pubitemid 34161303)
128. Araie M, Muta K. Effect of long-term topical betaxolol on tissue circulation in the iris and optic nerve head. Exp Eye Res. 1997;64:167-72. (Pubitemid 27139561)
129. Kim JH, Kim DM, Park WC. Effect of betaxolol on impaired choroidal blood flow after intravitreal injection of endothelin-1 in albino rabbits. J Ocul Pharmacol Ther. 2002;18:203-9. (Pubitemid 34701296)
130. Tamaki Y, Araie M, Tomita K, Nagahara M. Effect of topical betaxolol on tissue circulation in the human optic nerve head. J Ocul Pharmacol Ther. 1999;15:313-21. (Pubitemid 29375033)
131. Gupta A, Chen HC, Rassam SM, Kohner EM. Effect of betaxolol on the retinal circulation in eyes with ocular hypertension: a pilot study. Eye (London). 1994;8(Pt 6):668-71.
132. Erkin EF, Tarhan S, Kayikcioglu OR, Deveci H, Guler C, Goktan C. Effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma. Eur J Ophthalmol. 2004;14:211-9. (Pubitemid 38901792)
133. Di Carlo FJ, Leinweber FJ, Szpiech JM, Davidson IW. Metabolism of l-bunolol. Clin Pharmacol Ther. 1977;22:858-63. (Pubitemid 8402762)
134. Dong Y, Ishikawa H, Wu Y, Yoshitomi T. Vasodilatory mechanism of levobunolol on vascular smooth muscle cells. Exp Eye Res. 2007;84:1039-46. (Pubitemid 46770718)
135. Leung M, Grunwald JE. Short-term effects of topical levobunolol on the human retinal circulation. Eye (London). 1997;11(Pt 3):371-6. (Pubitemid 27344821)
136. Bloom AH, Grunwald JE, DuPont JC. Effect of one week of levobunolol HCl 0.5 % on the human retinal circulation. Curr Eye Res. 1997;16:191-6. (Pubitemid 27129961)
137. Bosem ME, Lusky M, Weinreb RN. Short-term effects of levobunolol on ocular pulsatile flow. Am J Ophthalmol. 1992;114:280-6.
138. Kanno M, Araie M, Koibuchi H, Masuda K. Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans. Br J Ophthalmol. 2000;84:293-9. (Pubitemid 30251686)
139. Sugiyama T, Kida T, Mizuno K, Kojima S, Ikeda T. Involvement of nitric oxide in the ocular hypotensive action of nipradilol. Curr Eye Res. 2001;23:346-51. (Pubitemid 34264322)
140. Araki H, Itoh M, Nishi K. Effects of nipradilol on the microvascular tone of rat mesentery: comparison with other beta-blockers and vasodilators. Arch Int Pharmacodyn Ther. 1992;318:47-54.
141. Yoshitomi T, Yamaji K, Ishikawa H, Ohnishi Y. Vasodilatory effects of nipradilol, an alpha- and beta-adrenergic blocker with nitric oxide releasing action, in rabbit ciliary artery. Exp Eye Res. 2002;75:669-76. (Pubitemid 36034631)
142. Kanno M, Araie M, Tomita K, Sawanobori K. Effects of topical nipradilol, a beta-blocking agent with alpha-blocking and nitroglycerin-like activities, on aqueous humor dynamics and fundus circulation. Investig Ophthalmol Vis Sci. 1998;39:736-43. (Pubitemid 28207468)
143. Kida T, Sugiyama T, Harino S, Kitanishi K, Ikeda T. The effect of nipradilol, an alpha-beta blocker, on retinal blood flow in healthy volunteers. Curr Eye Res. 2001;23:128-32. (Pubitemid 34499635)
144. Nakanishi M, Sugiyama T, Nakajima M, Ikeda T. Changes in orbital hemodynamics induced by nipradilol in healthy volunteers. J Ocul Pharmacol Ther. 2004;20:25-33. (Pubitemid 38199329)
145. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-8. (Pubitemid 23296779)
146. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-304. (Pubitemid 23274021)
147. Alm A, Villumsen J, Tornquist P, Mandahl A, Airaksinen J, Tuulonen A, et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology 1993;100:1312-6 (discussion 6-7).
148. Ishikawa H, Yoshitomi T, Mashimo K, Nakanishi M, Shimizu K. Pharmacological effects of latanoprost, prostaglandin E2, and F2alpha on isolated rabbit ciliary artery. Graefes Arch Clin Exp Ophthalmol. 2002;240:120-5. (Pubitemid 36075586)
149. Ishii K, Tomidokoro A, Nagahara M, Tamaki Y, Kanno M, Fukaya Y, et al. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans. Investig Ophthalmol Vis Sci. 2001;42:2957-63. (Pubitemid 33035296)
150. Ohashi M, Mayama C, Ishi K, Araie M. Local effect of topical FP-receptor agonists on retinal vessels of the ipsilateral posterior retina in normal rabbit eyes. Clin Exp Ophthalmol. 2008;36:767-74.
151. Ohashi M, Mayama C, Ishii K, Araie M. Effects of topical travoprost and unoprostone on optic nerve head circulation in normal rabbits. Curr Eye Res. 2007;32:743-9. (Pubitemid 47450625)
152. Seong GJ, Lee HK, Hong YJ. Effects of 0.005 % latanoprost on optic nerve head and peripapillary retinal blood flow. Ophthalmologica. 1999;213:355-9. (Pubitemid 29524921)
153. Gherghel D, Hosking SL, Cunliffe IA, Armstrong RA. First-line therapy with latanoprost 0.005 % results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study. Eye (London) 2008;22:363-9. (Pubitemid 351404460)
154. Tamaki Y, Nagahara M, Araie M, Tomita K, Sandoh S, Tomidokoro A. Topical latanoprost and optic nerve head and retinal circulation in humans. J Ocul Pharmacol Ther. 2001;17:403-11. (Pubitemid 33116117)
155. Harris A, Migliardi R, Rechtman E, Cole CN, Yee AB, Garzozi HJ. Comparative analysis of the effects of dorzolamide and latanoprost on ocular hemodynamics in normal tension glaucoma patients. Eur J Ophthalmol. 2003;13:24-31. (Pubitemid 36362895)
156. Zeitz O, Matthiessen ET, Reuss J, Wiermann A, Wagenfeld L, Galambos P, et al. Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]. BMC Ophthalmol. 2005;5:6. (Pubitemid 40746218)
157. Inan UU, Ermis SS, Yucel A, Ozturk F. The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial. Acta Ophthalmol Scand. 2003;81:155-60. (Pubitemid 36609217)
158. Sponsel WE, Mensah J, Kiel JW, Remky A, Trigo Y, Baca W, et al. Effects of latanoprost and timolol-XE on hydrodynamics in the normal eye. Am J Ophthalmol. 2000;130:151-9.
159. Geyer O, Man O, Weintraub M, Silver DM. Acute effect of latanoprost on pulsatile ocular blood flow in normal eyes. Am J Ophthalmol. 2001;131:198-202. (Pubitemid 32157033)
160. Sponsel WE, Paris G, Trigo Y, Pena M, Weber A, Sanford K, et al. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Am J Ophthalmol. 2002;133:11-8. (Pubitemid 34076499)
161. Vetrugno M, Cantatore F, Gigante G, Cardia L. Latanoprost 0.005 % in POAG: effects on IOP and ocular blood flow. Acta Ophthalmol Scand Suppl. 1998;227:40-1. (Pubitemid 29046198)
162. McKibbin M, Menage MJ. The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. Eye (London). 1999;13(Pt 1):31-4. (Pubitemid 29121594)
163. Georgopoulos GT, Diestelhorst M, Fisher R, Ruokonen P, Krieglstein GK. The short-term effect of latanoprost on intraocular pressure and pulsatile ocular blood flow. Acta Ophthalmol Scand. 2002;80:54-8. (Pubitemid 34506344)
164. Sponsel WE, Paris G, Trigo Y, Pena M. Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma. Am J Ophthalmol. 2002;134:552-9. (Pubitemid 35304645)
165. Sakurai M, Araie M, Oshika T, Mori M, Masuda K, Ueno R, et al. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol. 1991;35:156-65.
166. Azuma I, Masuda K, Kitazawa Y, Takase M, Yamamura H. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol. 1993;37:514-25. (Pubitemid 24029376)
167. Hayashi E, Yoshitomi T, Ishikawa H, Hayashi R, Shimizu K. Effects of isopropyl unoprostone on rabbit ciliary artery. Jpn J Ophthalmol. 2000;44:214-20. (Pubitemid 30417509)
168. Yu DY, Su EN, Cringle SJ, Schoch C, Percicot CP, Lambrou GN. Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Investig Ophthalmol Vis Sci. 2001;42:1499-504. (Pubitemid 32520741)
169. Sugiyama T, Azuma I. Effect of UF-021 on optic nerve head circulation in rabbits. Jpn J Ophthalmol. 1995;39:124-9.
170. Kimura I, Shinoda K, Tanino T, Ohtake Y, Mashima Y. Effect of topical unoprostone isopropyl on optic nerve head circulation in controls and in normal-tension glaucoma patients. Jpn J Ophthalmol. 2005;49:287-93. (Pubitemid 41264803)
171. Beano F, Orgul S, Stumpfig D, Gugleta K, Flammer J. An evaluation of the effect of unoprostone isopropyl 0.15 % on ocular hemodynamics in normal-tension glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2001;239:81-6. (Pubitemid 32288456)
172. Tamaki Y, Araie M, Tomita K, Nagahara M, Sandoh S, Tomidokoro A. Effect of topical unoprostone on circulation of human optic nerve head and retina. J Ocul Pharmacol Ther. 2001;17:517-27. (Pubitemid 34019979)
173. Makimoto Y, Sugiyama T, Kojima S, Azuma I. Long-term effect of topically applied isopropyl unoprostone on microcirculation in the human ocular fundus. Jpn J Ophthalmol. 2002;46:31-5. (Pubitemid 34195470)
174. Polska E, Doelemeyer A, Luksch A, Ehrlich P, Kaehler N, Percicot CL, et al. Partial antagonism of endothelin 1-induced vasoconstriction in the human choroid by topical unoprostone isopropyl. Arch Ophthalmol. 2002;120:348-52. (Pubitemid 34250057)
175. Sugiyama T, Mashima Y, Yoshioka Y, Oku H, Ikeda T. Effect of unoprostone on topographic and blood flow changes in the ischemic optic nerve head of rabbits. Arch Ophthalmol. 2009;127:454-9.
176. Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, Vandenburgh AM. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131:19-24. (Pubitemid 32037003)
177. Brandt JD, VanDenburgh AM, Chen K, Whitcup SM. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001;108:1023-31 (discussion 32). (Pubitemid 32500015)
178. Goldberg I, Cunha-Vaz J, Jakobsen JE, Nordmann JP, Trost E, Sullivan EK. Comparison of topical travoprost eye drops given once daily and timolol 0.5 % given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10:414-22. (Pubitemid 33062659)
179. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-84. (Pubitemid 32904567)
180. Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767-76. (Pubitemid 38252953)
181. Sutton A, Gilvarry A, Ropo A. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2007;23:359-65. (Pubitemid 350195060)
182. Aihara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2010;4:163-70.
183. Allemann R, Flammer J, Haefliger IO. Vasoactive properties of bimatoprost in isolated porcine ciliary arteries. Klin Monbl Augenheilkd. 2003;220:161-4. (Pubitemid 36402470)
184. Allemann R, Flammer J, Haefliger IO. Absence of vasoactive properties of travoprost in isolated porcine ciliary arteries. Klin Monbl Augenheilkd. 2003;220:152-5. (Pubitemid 36402468)
185. Inan UU, Ermis SS, Orman A, Onrat E, Yucel A, Ozturk F, et al. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. J Ocul Pharmacol Ther. 2004;20:293-310. (Pubitemid 39108894)
186. Akarsu C, Yilmaz S, Taner P, Ergin A. Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2004;242:814-8. (Pubitemid 39485530)
187. Chen MJ, Cheng CY, Chen YC, Chou CK, Hsu WM. Effects of bimatoprost 0.03 % on ocular hemodynamics in normal tension glaucoma. J Ocul Pharmacol Ther. 2006;22:188-93. (Pubitemid 44051131)
188. Izumi N, Nagaoka T, Sato E, Mori F, Takahashi A, Sogawa K, et al. Short-term effects of topical tafluprost on retinal blood flow in cats. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2008;24:521-6.
189. Akaishi T, Kurashima H, Odani-Kawabata N, Ishida N, Nakamura M. Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits. J Ocul Pharmacol Ther. 2010;26:181-6.
190. Kurashima H, Watabe H, Sato N, Abe S, Ishida N, Yoshitomi T. Effects of prostaglandin F(2alpha) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost. Exp Eye Res. 2010;91:853-9.
191. Dobbs PC, Epstein DL, Anderson PJ. Identification of isoenzyme C as the principal carbonic anhydrase in human ciliary processes. Investig Ophthalmol Vis Sci. 1979;18:867-70. (Pubitemid 9212719)
192. Wistrand PJ, Schenholm M, Lonnerholm G. Carbonic anhydrase isoenzymes CA I and CA II in the human eye. Investig Ophthalmol Vis Sci. 1986;27:419-28. (Pubitemid 16129930)
193. Wistrand PJ, Garg LC. Evidence of a high-activity C type of carbonic anhydrase in human ciliary processes. Investig Ophthalmol Vis Sci. 1979;18:802-6. (Pubitemid 9212709)
194. Lindskog S. Structure and mechanism of carbonic anhydrase. Pharmacol Ther. 1997;74:1-20. (Pubitemid 27337350)
195. Wang RF, Serle JB, Podos SM, Sugrue MF. MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys. Arch Ophthalmol. 1991;109:1297-9.
196. Sugrue MF. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1996;12:363-76. (Pubitemid 26335456)
197. Maren TH, Conroy CW, Wynns GC, Levy NS. Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1997;13:23-30. (Pubitemid 27130719)
198. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000;19:87-112.
199. Barnes GE, Li B, Dean T, Chandler ML. Increased optic nerve head blood flow after 1 week of twice daily topical brinzolamide treatment in Dutch-belted rabbits. Surv Ophthalmol. 2000;44(Suppl 2):S131-40. (Pubitemid 30138040)
200. Tamaki Y, Araie M, Muta K. Effect of topical dorzolamide on tissue circulation in the rabbit optic nerve head. Jpn J Ophthalmol. 1999;43:386-91. (Pubitemid 29415733)
201. Grunwald JE, Mathur S, DuPont J. Effects of dorzolamide hydrochloride 2 % on the retinal circulation. Acta Ophthalmol Scand. 1997;75:236-8. (Pubitemid 27315583)
202. Pillunat LE, Bohm AG, Koller AU, Schmidt KG, Klemm M, Richard G. Effect of topical dorzolamide on optic nerve head blood flow. Graefes Arch Clin Exp Ophthalmol. 1999;237:495-500. (Pubitemid 29253544)
203. Faingold D, Hudson C, Flanagan J, Guan K, Rawji M, Buys YM, et al. Assessment of retinal hemodynamics with the Canon laser blood flowmeter after a single dose of 2 % dorzolamide hydrochloride eyedrops. Can J Ophthalmol. 2004;39:506-10. (Pubitemid 39209193)
204. Simsek T, Yanik B, Conkbayir I, Zilelioglu O. Comparative analysis of the effects of brimonidine and dorzolamide on ocular blood flow velocity in patients with newly diagnosed primary open-angle glaucoma. J Ocul Pharmacol Ther. 2006;22:79-85. (Pubitemid 43742943)
205. Harris A, Arend O, Kagemann L, Garrett M, Chung HS, Martin B. Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. J Ocul Pharmacol Ther. 1999;15:189-97. (Pubitemid 29262975)
206. Harris A, Arend O, Chung HS, Kagemann L, Cantor L, Martin B. A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients. Ophthalmology. 2000;107:430-4. (Pubitemid 30191361)
207. Venkataraman ST, Hudson C, Rachmiel R, Buys YM, Markowitz SN, Fisher JA, et al. Retinal arteriolar vascular reactivity in untreated and progressive primary open-angle glaucoma. Investig Ophthalmol Vis Sci. 2010;51:2043-50.
208. Kaup M, Plange N, Niegel M, Remky A, Arend O. Effects of brinzolamide on ocular haemodynamics in healthy volunteers. Br J Ophthalmol. 2004;88:257-62. (Pubitemid 38142099)
209. Iester M, Altieri M, Michelson G, Vittone P, Traverso CE, Calabria G. Retinal peripapillary blood flow before and after topical brinzolamide. Ophthalmologica. 2004;218:390-6. (Pubitemid 39551809)
210. Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox; a preliminary report. Am J Ophthalmol. 1954;37:13-5.
211. Reber F, Gersch U, Funk RW. Blockers of carbonic anhydrase can cause increase of retinal capillary diameter, decrease of extracellular and increase of intracellular pH in rat retinal organ culture. Graefes Arch Clin Exp Ophthalmol. 2003;241:140-8. (Pubitemid 36747802)
212. Pedersen DB, Koch Jensen P, la Cour M, Kiilgaard JF, Eysteinsson T, Bang K, et al. Carbonic anhydrase inhibition increases retinal oxygen tension and dilates retinal vessels. Graefes Arch Clin Exp Ophthalmol. 2005;243:163-8. (Pubitemid 40372080)
213. Dallinger S, Bobr B, Findl O, Eichler HG, Schmetterer L. Effects of acetazolamide on choroidal blood flow. Stroke. 1998;29:997-1001. (Pubitemid 28228163)
214. Kiss B, Dallinger S, Findl O, Rainer G, Eichler HG, Schmetterer L. Acetazolamide-induced cerebral and ocular vasodilation in humans is independent of nitric oxide. Am J Physiol. 1999;276:R1661-7.
215. Kerty E, Horven I, Dahl A, Nyberg-Hansen R. Ocular and cerebral blood flow measurements in healthy subjects. A comparison of blood flow velocity and dynamic tonometry measurements before and after acetazolamide. Acta Ophthalmol (Cph). 1994;72:401-8. (Pubitemid 24302804)
216. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med. 1999;341:1447-57. (Pubitemid 29513462)
217. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med. 1982;307:1618-27. (Pubitemid 13250421)
218. Cohn JN. Calcium, vascular smooth muscle, and calcium entry blockers in hypertension. Ann Intern Med. 1983;98:806-9. (Pubitemid 13135267)
219. Hof RP. Calcium antagonist and the peripheral circulation: differences and similarities between PY 108-068, nicardipine, verapamil and diltiazem. Br J Pharmacol. 1983;78:375-94. (Pubitemid 13192209)
220. 2+ channel function and drug action. Trends Pharmacol Sci. 1995;16:43-9.
221. Payne LJ, Slagle TM, Cheeks LT, Green K. Effect of calcium channel blockers on intraocular pressure. Ophthalmic Res. 1990;22:337-41.
222. Segarra J, Santafe J, Garrido M, Martinez de Ibarreta MJ. The topical application of verapamil and nifedipine lowers intraocular pressure in conscious rabbits. Gen Pharmacol. 1993;24:1163-71. (Pubitemid 23283085)
223. Monica ML, Hesse RJ, Messerli FH. The effect of a calcium-channel blocking agent on intraocular pressure. Am J Ophthalmol. 1983;96:814. (Pubitemid 14204233)
224. Abelson MB, Gilbert CM, Smith LM. Sustained reduction of intraocular pressure in humans with the calcium channel blocker verapamil. Am J Ophthalmol. 1988;105:155-9. (Pubitemid 18081310)
225. Netland PA, Feke GT, Konno S, Goger DG, Fujio N. Optic nerve head circulation after topical calcium channel blocker. J Glaucoma. 1996;5:200-6. (Pubitemid 26195689)
226. Erickson KA, Schroeder A, Netland PA. Verapamil increases outflow facility in the human eye. Exp Eye Res. 1995;61:565-7.
227. Melena J, Zalduegui A, Arcocha P, Santafe J, Segarra J. Topical verapamil lowers outflow facility in the rabbit eye. J Ocul Pharmacol Ther. 1999;15:199-205. (Pubitemid 29262976)
228. Tomita K, Araie M, Tamaki Y, Nagahara M, Sugiyama T. Effects of nilvadipine, a calcium antagonist, on rabbit ocular circulation and optic nerve head circulation in NTG subjects. Investig Ophthalmol Vis Sci. 1999;40:1144-51. (Pubitemid 29211451)
229. Luksch A, Rainer G, Koyuncu D, Ehrlich P, Maca T, Gschwandtner ME, et al. Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma. Br J Ophthalmol. 2005;89:21-5. (Pubitemid 40040232)
230. Nyborg NC, Prieto D, Benedito S, Nielsen PJ. Endothelin-1-induced contraction of bovine retinal small arteries is reversible and abolished by nitrendipine. Investig Ophthalmol Vis Sci. 1991;32(1):27-31.
231. Meyer P, Lang MG, Flammer J, Luscher TF. Effects of calcium channel blockers on the response to endothelin-1, bradykinin and sodium nitroprusside in porcine ciliary arteries. Exp Eye Res. 1995;60:505-10.
232. Lang MG, Zhu P, Meyer P, Noll G, Haefliger IO, Flammer J, et al. Amlodipine and benazeprilat differently affect the responses to endothelin-1 and bradykinin in porcine ciliary arteries: effects of a low and high dose combination. Curr Eye Res. 1997;16:208-13. (Pubitemid 27129963)
233. Harino S, Riva CE, Petrig BL. Intravenous nicardipine in cats increases optic nerve head but not retinal blood flow. Investig Ophthalmol Vis Sci. 1992;33:2885-90.
234. Tamaki Y, Araie M, Tomita K, Urashima H. Effects of pranidipine, a new calcium antagonist, on circulation in the choroid, retina and optic nerve head. Curr Eye Res. 1999;19:241-7. (Pubitemid 29500272)
235. Shimazawa M, Sugiyama T, Azuma I, Araie M, Iwakura Y, Watari M, et al. Effect of lomerizine, a new Ca(2+)channel blocker, on the microcirculation in the optic nerve head in conscious rabbits: a study using a laser speckle technique. Exp Eye Res. 1999;69:185-93. (Pubitemid 29369293)
236. Tamaki Y, Araie M, Fukaya Y, Nagahara M, Imamura A, Honda M, et al. Effects of lomerizine, a calcium channel antagonist, on retinal and optic nerve head circulation in rabbits and humans. Investig Ophthalmol Vis Sci. 2003;44:4864-71. (Pubitemid 37315302)
237. Waki M, Sugiyama T, Watanabe N, Ogawa T, Shirahase H, Azuma I. Effect of topically applied iganidipine dihydrochloride, a novel calcium antagonist, on optic nerve head circulation in rabbits. Jpn J Ophthalmol. 2001;45:76-83. (Pubitemid 32015896)
238. Kitazawa Y, Shirai H, Go FJ. The effect of Ca2(+)-antagonist on visual field in low-tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 1989;227:408-12. (Pubitemid 19221110)
239. Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am J Ophthalmol. 1993;115:608-13. (Pubitemid 23137645)
240. Gaspar AZ, Flammer J, Hendrickson P. Influence of nifedipine on the visual fields of patients with optic-nerve-head diseases. Eur J Ophthalmol. 1994;4:24-8. (Pubitemid 24110393)
241. Geyer O, Neudorfer M, Kessler A, Firsteter E, Lazar M, Almog Y. Effect of oral nifedipine on ocular blood flow in patients with low tension glaucoma. Br J Ophthalmol. 1996;80:1060-2. (Pubitemid 27010840)
242. Wilson RP, Chang WJ, Sergott RC, Moster MR, Schmidt CM, Bond JB, et al. A color Doppler analysis of nifedipine-induced posterior ocular blood flow changes in open-angle glaucoma. J Glaucoma. 1997;6:231-6. (Pubitemid 27503659)
243. Schmidt KG, Mittag TW, Pavlovic S, Hessemer V. Influence of physical exercise and nifedipine on ocular pulse amplitude. Graefes Arch Clin Exp Ophthalmol. 1996;234:527-32.
244. Harris A, Evans DW, Cantor LB, Martin B. Hemodynamic and visual function effects of oral nifedipine in patients with normal-tension glaucoma. Am J Ophthalmol. 1997;124:296-302. (Pubitemid 27383094)
245. Van den Kerckhoff W, Drewes L. Transfer of the Ca-antagonists nifedipine and nimodipine across the blood-brain barrier and their regional distribution in vivo. J Cereb Blood Flow Metab. 1985;5:S459-60.
246. Michalk F, Michelson G, Harazny J, Werner U, Daniel WG, Werner D. Single-dose nimodipine normalizes impaired retinal circulation in normal tension glaucoma. J Glaucoma. 2004;13:158-62. (Pubitemid 38372828)
247. Boehm AG, Breidenbach KA, Pillunat LE, Bernd AS, Mueller MF, Koeller AU. Visual function and perfusion of the optic nerve head after application of centrally acting calcium-channel blockers. Graefes Arch Clin Exp Ophthalmol. 2003;241:34-8. (Pubitemid 36747785)
248. Piltz JR, Bose S, Lanchoney D. The effect of nimodipine, a centrally active calcium antagonist, on visual function and mascular blood flow in patients with normal-tension glaucoma and control subjects. J Glaucoma. 1998;7:336-42. (Pubitemid 30246088)
249. Tomita G, Niwa Y, Shinohara H, Hayashi N, Yamamoto T, Kitazawa Y. Changes in optic nerve head blood flow and retrobular hemodynamics following calcium-channel blocker treatment of normal-tension glaucoma. Int Ophthalmol. 1999;23:3-10.
250. Yamamoto T, Niwa Y, Kawakami H, Kitazawa Y. The effect of nilvadipine, a calcium-channel blocker, on the hemodynamics of retrobulbar vessels in normal-tension glaucoma. J Glaucoma. 1998;7(5):301-5. (Pubitemid 30246082)
251. Netland PA, Grosskreutz CL, Feke GT, Hart LJ. Color Doppler ultrasound analysis of ocular circulation after topical calcium channel blocker. Am J Ophthalmol. 1995;119(6):694-700.
252. Koseki N, Araie M, Tomidokoro A, Nagahara M, Hasegawa T, Tamaki Y, et al. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology. 2008;115:2049-57.